. 2020 Apr 11;9(4):1093. doi: 10.3390/jcm9041093

Table 2.

Cox regression analysis for the cardiac wild-type transthyretin amyloidosis cohort.

Variable	Crude Hazard Ratio	95% Confidence Interval	p Value	Adjusted Hazard Ratio	95% Confidence Interval	p Value
	Univariable Regression			Multivariable Regression
Clinical parameters
Age, years	1.143	1.021–1.279	0.020	1.255	1.055–1.493	0.010
Sex, male gender	2.252	0.284–17.843	0.442	0.387	0.025–5.987	0.497
NYHA functional class ≥ III	1.441	0.379–5.485	0.592	2.927	0.662–12.931	0.157
Systolic blood pressure, mmHg	0.990	0.955–1.027	0.602	0.985	0.954–1.017	0.353
Diastolic blood pressure, mmHg	0.966	0.906–1.029	0.283	0.897	0.828–0.971	0.008
NT-proBNP, pg/mL*	1.383	0.769–2.487	0.279	1.181	0.641–2.176	0.593
Troponin t, ng/mL †	2.499	1.231–5.072	0.011	2.466	1.187–5.124	0.016
eGFR, mL/min/1.73 m²	0.989	0.962–1.017	0.442	0.991	0.957–1.027	0.630
Concomitant medication
Beta Blocker	0.716	0.187–2.733	0.625	0.607	0.110–3.340	0.566
ACE inhibitor	0.868	0.173–4.347	0.863	1.024	0.180–5.816	0.979
Angiotensin receptor blocker	1.044	0.260–4.184	0.952	0.1756	0.391–7.893	0.463
Number of diuretic agents	1.276	0.619–2.630	0.509	5.932	1.217–28.906	0.028
Invasive hemodynamic parameters
Mean pulmonary arterial pressure, mmHg	1.177	1.049–1.321	0.005	1.130	1.006–1.269	0.040
Right atrial pressure, mmHg	1.124	0.992–1.273	0.067	1.057	0.926–1.205	0.411
Pulmonary artery wedge pressure, mmHg	1.116	0.995–1.253	0.061	1.045	0.924–1.182	0.484
Cardiac index, L/min/m²	0.920	0.338–2.502	0.870	0.656	0.248–1.739	0.397
Stroke volume index, mL/m²	0.974	0.920–1.031	0.369	0.950	0.890–1.014	0.124
Pulmonary vascular resistance, dyn·s·cm⁻⁵	1.005	0.999–1.010	0.086	1.010	1.000–1.020	0.046
Diastolic pressure gradient, mmHg	0.948	0.795–1.130	0.552	1.036	0.851–1.260	0.727
Cardiac magnetic resonance imaging parameters
MOLLI-ECV, %	1.064	1.001–1.131	0.045	1.044	0.980–1.111	0.181
Left atrial area, cm²	1.120	0.993–1.264	0.065	1.081	0.940–1.241	0.274
Right atrial area, cm²	1.012	0.927–1.104	0.792	1.010	0.901–1.132	0.870
Left ventricular ejection fraction, %	0.981	0.921–1.045	0.554	1.031	0.939–1.133	0.524
Left ventricular end-diastolic volume index, mL/m² (IQR)	1.016	0.974–1.060	0.468	0.984	0.932–1.040	0.569
Interventricular septum, mm	1.058	0.884–1.267	0.536	1.005	0.851–1.188	0.950
Right ventricular ejection fraction, %	0.973	0.924–1.025	0.297	0.990	0.931–1.053	0.757
Right ventricular end-diastolic volume index, mL/m² (IQR)	1.009	0.993–1.026	0.260	1.022	0.975–1.071	0.370
Transthorathic echocardiography parameters
Significant aortic valve stenosis	1.664	0.191–14.515	0.645	5.781	0.417–80.052	0.191
Significant aortic valve regurgitation	1.664	0.191–14.515	0.645	5.781	0.417–80.052	0.191
Significant mitral valve regurgitation	1.118	0.314–3.982	0.864	0.230	0.044–1.197	0.081

New York Heart Association (NYHA); N-terminal prohormone of brain natriuretic peptide (NT-proBNP); estimated glomerular filtration rate (eGFR); angiotensin converting enzyme (ACE); modified Look–Locker inversion recovery sequence derived extracellular volume (MOLLI-ECV). Valvular stenosis or regurgitation ≥ moderate was considered significant. *NT-proBNP was graded into quartiles. †Troponin T was graded into quartiles. Bold indicates statistical significance.